A major obstacle to winning the war on cancer is a lack of understanding of how cancer develops. The dominant theory for the last 50 years has been the somatic mutation theory (SMT), which says that cancer arises directly from a sequence of genetic changes on a cell that leads to its proliferation. The alternative tissue organization field theory (TOFT) says that cancers arise from a disruption of cell communication needed to maintain normal tissue architecture. A historical background places these theories into perspective. Various experimental results are paradoxical under SMT, but readily explained under TOFT, suggesting paradigm instability. These paradoxical results offer new opportunities for cancer research.
Get full access to this article
View all access options for this article.
References
1.
BakerSG, CappuccioA, PotterJD. Research on early-stage carcinogenesis: Are we approaching paradigm instability?J Clin Oncol., 2010; 28:3215–3218.
2.
VauxDL. In defense of the somatic mutation theory of cancer. Bioessays., 2012; 33:341–343.
3.
SotoAM, SonnenscheinCS. The tissue organization field theory of cancer: A testable replacement for the somatic mutation theory. Bioessays., 2011; 5:332–340.
4.
SotoAM, SonnenscheinCS. The somatic mutation theory of cancer: Growing problems with the paradigm. BioEssays., 2005; 26:1097–1107.
5.
PotterJD. Morphostats: A missing concept in cancer biology. Cancer Epidemiol Biomarkers Prev., 2001; 10:161–1799.
BakerSG, KramerBS. Paradoxes in carcinogenesis: New opportunities for research directions. BMC Cancer., 2007; 7:151.
9.
PlimmerHG. The parasitic theory of cancer. Br Med J., 1903; 2:1511–1515.
10.
WeinbergRA. In Retrospect: The chromosome trail. Nature., 2008; 453:725.
11.
TyzzerEE. Tumor immunity. J Cancer Res., 1916; 1:125–155.
12.
EdlerL, Kopp-SchneiderA. Origins of the mutational origin of cancer. Int J Epidemiol., 2005; 34:1168–1170.
13.
McCombsRS, McCombsRP. A hypothesis on the causation of cancer. Science, 1930; 72:423–424.
14.
DollR. Commentary: The age distribution of cancer and a multistage theory of carcinogenesis. Int J Epidemiol., 2004; 33:1183–1184.
15.
FisherJC, HollomanJH. A hypothesis for the origin of cancer foci. Cancer, 1951; 4:916–918.
16.
FouldL. The experimental study of tumor progression: A review. Cancer Res., 1954; 14:327–339.
17.
RousP, BeardJW. The progression to carcinoma of virus-induced rabbit papillomas (Shope)J Exp Med., 1935; 62:523–548.
18.
ArmitageP, DollR. The age distribution of cancer and aa multi-stage theory of carcingoeneesis. Br J Cancer, 1954; 8:1–12.
19.
PlattR. Clonal ageing and cancer. Lancet, 1955; 1:867.
20.
ArmitageP, DollR. A two-stage theory of carcinogenesis in relation to the age distribution of human cancer. Br J Cancer, 1957; 11:161–169.
21.
FisherJ. Multiple-mutation theory of carcinogenesis. Nature, 1958; 181:651–652.
22.
RousP. Surmise and fact on the nature of cancer. Nature, 1959; 183:1357–1361.
23.
NowellPC. Discovery of the Philadelphia chromosome: A personal perspective. J Clin Invest., 2007; 117:2033–2035.
24.
NowellPC, HungerfordDA. A minute chromosome in human chronic granulocytic leukemia. Science, 1960; 132:1488–1501.
25.
WatsonJD, CrickFHC. A structure for deoxyribose nucleic acid. Nature, 1953; 171:737–738.
26.
Van EppsHL. Peyton Rous father of the tumor virus. J Exp Med., 2005; 201:320.
27.
HuebnerRJ, TodaroGJ. Oncogenes of RNA tumor viruses as determinants of cancer. Proc Natl Acad Sci., 1969; 64:1087–1094.
28.
StehelinD, VarmusHE, BishopJMet al.DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature, 1976; 260:170–173.
29.
JavierRT, ButelJS. The history of tumor virology. Cancer Res., 2008; 68:7693–7706.
30.
ShihC, PadhyLC, MurrayMet al.Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature, 1981; 290:261–264.
31.
StrattonMR, CampbellPJ, FutrealPA. The cancer genome. Nature, 2009; 458:719–724.
32.
VarmusHE. The molecular genetics of cellular oncogenes. Ann Rev Genet., 1984; 18:553–612.
33.
AdamsJM, HarrisAW, PinkertCAet al.The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature, 1985; 318:533–538.
34.
HarrisH. Cell fusion and the analysis of malignancy. Proc R Soc Lond B Biol Sci., 1971; 179:1–20.
35.
FriendSH, BernardsR, RogeljSet al.A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature, 1986; 323:643–646.
36.
SjoblomT, JonesS, WoodLDet al.The consensus coding sequences of human breast and colorectal cancers. Science, 2006; 314:268–274.
37.
FutrealPA, CoinL, MarshallMet al.A census of human cancer genes. Nat Rev Cancer, 2004; 4:177–183.
38.
HahnWC, WeinbergRA. Rules for making tumor cells. N Eng J Med., 2002; 347:1593–1603.
39.
LoebLA. A mutator phenotype in cancer. Cancer Res., 2001; 61:3230–3239.
40.
GreenmanC, StephensP, SmithRet al.Patterns of somatic mutation in human cancer genomes. Nature, 2007; 446:153–158.
41.
BocaSM, KinzlerKW, VelculescuVEet al.Patient-oriented gene set analysis for cancer mutation data. Genome Biol., 2010; 11:R112.
42.
HornberJJ, BruggmanFJ, WesterhoffHVet al.Cancer: A systems biology disease. BioSystems, 2006; 83:81–90.
43.
BakerSG, KramerBS. Systems biology and cancer: Promises and perils. Prog Biophys Mol Bio., 2011; 106:410–413.
44.
SpielbergN, AndersonBD. Seven Ideas That Shook the Universe. New York, NY: John Wiley and Sons, 1987.
45.
SonnenscheinC, SotoAM. The Society of Cells: Cancer and Control of Cell Proliferation. New York, NY: Springer Verlag, 1999.
46.
KardinalCG, YarbroJW. A conceptual history of cancer. Semin Oncol., 1979; 6:396–408.
47.
OberlingC. The Riddle of Cancer. New Haven, CT: Yale University Press, 1946; 26–27.
48.
NaxerovaK, BultCJ, PeastonAet al.Analysis of gene expression in a developmental context emphasizes distinct biological leitmotifs in human cancers. Genome Biol., 2008; 9:R108.
49.
SellS. Cellular origin of cancer: Dedifferentiation or stem cell maturation arrest?Environ Health Perspect, 1993; 101:15–26.
50.
TrioloVA. Nineteenth century foundations of cancer research origins of experimental research. Cancer Res., 1964; 24:4–27.
51.
GurdonJ, DysonS, JohnstonD. Cells' perception of position in a concentration gradient. Cell, 1998; 95:159–162.
52.
SanderK. Of gradients and genes: Developmental concepts of Theodor Boveri and his students. Dev Genes Evol., 1994; 203:295–297.
53.
OpitzJM, GilbertSF. Commentary. Int J Dev Biol., 1998; 41:771–779.
TuringAM. The chemical basis of morphogenesis. Philos Trans R Soc Lond B Biol Sci., 1952; 237:37–72.
56.
CrickF. Diffusion in embryogenesis. Nature, 1970; 225:420–422.
57.
DrieverW, Nusslein-VolhardC. The bicoid protein determines position in the Drosophila embryo in a concentration dependent manner. Cell, 1988; 54:95–104.
58.
NeedhamJ. New advances in chemistry and biology of organized growth. Proc Roy Soc B., 1936; 29:1577–1628.
59.
WaddingtonCH. Cancer and the theory of organizers. Nature, 1935; 125:606–608.
60.
RubinH. Cancer as a dynamic development disorder. Cancer Res., 1985; 45:2935–2942.
61.
TarinD. Tissue interactions in morphogenesis, morphostasis and carcinogenesis. J Theor Biol., 1972; 34:61–72.
62.
van den BrinkGRet al.Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. Gastroenterology, 2001; 121:317–328.
63.
McConnellG. The experimental production of epithelial proliferation. J Am Med Assn, 1907; 49:1498–1502.
64.
SnowC. An attempt to produce an atypical epithelial growth by injection of scharlach r. in olive oil; a control of Fischer's experiments. J Infect Dis., 1907; 4:385–396.
65.
BullockFD, RohdenburgGL. A study of the Scharlach R reaction and of allied forms of epithelial proliferation. J Med Res., 1915; 33:53–92.
66.
TurnerFC. Scarcomas at sites of subcutaneously implanted Bakelite disks in rates. J Natl Cancer Inst., 1941; 2:81–83.
67.
BischoffF, BrysonG. Carcinogenesis through solid state surfaces. Prog Exp Tumor Exp Tumor Res., 1964; 14:85–133.
68.
KarpRD, JohnsonKH, BuoenLCet al.Tumorigenesis by Millipore filters in mice: Histology and ultrastructure of tissue reactions as related to pore size. J Natl Cancer Inst., 1973; 51:1275–1285.
69.
OrrJW. The mechanism of chemical carcinogenesis. Br Med Bull., 1958; 14:99–101.
70.
MintzB, IllmenseeK. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc Natl Acad Sci., 1975; 72:3585–3589.
71.
IllmenseeK, MintzB. Totipotency and normal differentiation of single teratocarcinoma cells cloned by injection into blastocysts. Proc Natl Acad Sci., 1976; 73:549–553.
72.
MaffiniMV, SotoAM, CalabroJMet al.The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci., 2004; 117:1495–1502.
73.
MitelmanF, JohanssonF, MertensF. The impact of translocations and gene fusions on cancer causation. Net Rev Cancer, 2007; 7:233–245.
StephensPJ, GreenmanCD, FuBet al.Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell, 2011; 144:27–40.
76.
Nik-ZainalS, AlexandrovLB, WedgeDCet al.Mutational processes molding the genomes of 21 breast cancers. Cell, 2012; 149:979–993.
77.
SelturSR, LeeC. Tumor archeology reveals that mutations love company. Cell, 2012; 149:959–961.
78.
Nik-ZainalS, Van LooPB, WedgeDCet al.The life history of 21 breast cancers. Cell, 2012; 149:994–1007.
79.
WangX, WangM, MacLennanGTet al.Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst., 2009; 101:560–570.
80.
HiroshimaK, ToyozakiT, KohnoHet al.Synchronous and metachronous lung carcinomas: Molecular evidence for multicentricity. Pathol Int., 1998; 48:869–876.
81.
PodsypaninaK, PolitiK, BeverlyLJet al.Oncogene cooperation in tumor maintenance and tumor recurrence in mouse mammary tumors induced by Myc and mutant Kras. Proc Natl Acad Sci., 2008; 105:5242–5247.
82.
KhalafWF, WhiteH, WenningMJet al.K-Ras is essential for normal fetal liver erythropoiesis. Blood, 2005; 105:3538–3541.
83.
KantarjianH, SawyersC, HochhausAet al.Hematologic, cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med., 2002; 346:645–652.
84.
YabaA, KayisliUA, JohnsonJet al.The abelson tyrosine kinase (c-Abl) expression on the mouse uterus and placenta during gestational period. J Mol Histol., 2011; 2:91–96.
85.
GrayRS, CheungKJ, EwaldAJ. Cellular mechanisms regulating epithelial morphogenesis and cancer invasion. Curr Opin Cell Biol., 2010; 5:640–650.
86.
JohnsonKH, GhobrialHKG, BuoenLCet al.Nonfibroblastic origin of foreign body sarcomas implicated by histological and electron microscopic studies. Cancer Res., 1973; 33:3139–3154.
87.
BarnesDWH, EvansEP, LoutitJF. Local origin of fibroblasts deduced from sarcomas induced in chimaeras by implants of pliable disks. Nature, 1971; 233:267–268.
88.
NehlsV, DenzerK, DrenckhahnD. Pericyte involvement in capillary sprouting during angiogenesis in situ. Cell Tissue Res., 1992; 270:469–474.
89.
PasseyRD. Some problems of lung cancer. Lancet, 1962; 280:107–112.
90.
MizejewskiGJ. Biological roles of alpha-fetoprotein during pregnancy and perinatal development. Exp Biol Med., 2004; 229:439–463.
91.
SarandakouA, ProtonatariouE, RizosD. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci., 2007; 44:151–178.
92.
Schor SL SchorSM, GrayAMet al.Fetal and cancer patient fibroblasts produce autocrine migration-stimulating factor not made by normal adult cells. J Cell Sci., 1988; 90:391–399.
93.
AljoraniLE, BankfalviA, CareyFAet al.Migration-stimulating factor as a novel biomarker in salivary gland tumours. J Oral Pathol Med., 2011; 40:747–754.
94.
BakerSG. Simple, flexible classification via Swirls-and-Ripples. BMC Bioinformatics, 2010; 11:452.
95.
MaY, PengJ, LiuWet al.Proteomics identification of desmin as a potential oncofetal diagnostic and prognostic biomarker in colorectal cancer. Mol Cell Proteomics, 2009; 8:1878–1890.
96.
ArentzG, ChatawayT, PriceTJet al.Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels. Clin Proteomics., 2011; 8:16.
97.
BakerSG. Improving the biomarker pipeline to develop and evaluate cancer screening tests. J Natl Cancer Inst., 2009; 101:1116–1119.
98.
MurrayMJ, LesseyBA. Embryo implantation and tumor metastasis: Common pathways of invasion and angiogenesis. Semin Reprod Med., 1999; 17:275–290.
99.
SchaefferEM, MarchionniL, HuangZet al.Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene, 2008; 27:7180–7191.
100.
WeinbergRA. Coevolution in the tumor microenvironment. Nat Gen., 2008; 40:494–495.
101.
BissellMJ, HinesWC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med., 2011; 17:320–328.
102.
QiuW, HuM, SridharAet al.No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet., 2008; 40:650–655.
103.
PianaR. MD Anderson Cancer Center's new president has a bold vision. A conversation with Ronald A. DePinho, MD. The ASCO Post., 2012; 3:1.
104.
AktipisCA, MaleyCC, PepperJW. Dispersal evolution in neoplasms: The role of disregulated metabolism in the evolution of cell motility. Cancer Prev Res., 2012; 5:266–275.
105.
BakerSG, SotoAM, SonnenscheinCet al.Plausibility of stromal initiation of epithelial cancers without a mutation in the epithelium: A computer simulation of morphostats. BMC Cancer, 2009; 9:89.
106.
LambertCG, BlackLJ. Learning from out GWAS mistakes: From experimental design to scientific method. Biostatistics, 2012; 13:195–203.
107.
StrattonMR. Exploring the genomes of cancer cells. Progress and promise. Science, 1011; 331:1553–1558.
108.
ThomasL. The Lives of a Cell. Notes of a Biology Watcher. New York, NY: Penguin Books, 1974.
109.
MooreR. Niels Bohr: The Man, His Science, and the World They Changed. New York, NY: Alfred Knopf, 1966; 196.
